U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H12N4O5S
Molecular Weight 300.2926
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAZOBACTAM

SMILES

C[C@]1(Cn2ccnn2)[C@]([H])(C(=O)O)N3C(=O)C[C@@]3([H])S1(=O)=O

InChI

InChIKey=LPQZKKCYTLCDGQ-WEDXCCLWSA-N
InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1

HIDE SMILES / InChI
Tazobactam is a beta-lactamase inhibitor, which was approved by FDA for the treatment of wide range of bacterial infections either in combination with piperacillin (Zosyn) or with ceftolozane (Zerbaxa).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.01 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ZOSYN

Approved Use

ZOSYN is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a beta-lactamase inhibitor, tazobactam, indicated for the treatment of patients with intra-abdominal infections; skin and skin structure infections; female pelvic infections; community-acquired pneumonia; nosocomial pneumonia.

Launch Date

7.5124802E11
Curative
ZOSYN

Approved Use

ZOSYN is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a beta-lactamase inhibitor, tazobactam, indicated for the treatment of patients with intra-abdominal infections; skin and skin structure infections; female pelvic infections; community-acquired pneumonia; nosocomial pneumonia.

Launch Date

7.5116157E11
Curative
ZOSYN

Approved Use

ZOSYN is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a beta-lactamase inhibitor, tazobactam, indicated for the treatment of patients with intra-abdominal infections; skin and skin structure infections; female pelvic infections; community-acquired pneumonia; nosocomial pneumonia.

Launch Date

7.5116157E11
Curative
ZOSYN

Approved Use

ZOSYN is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a beta-lactamase inhibitor, tazobactam, indicated for the treatment of patients with intra-abdominal infections; skin and skin structure infections; female pelvic infections; community-acquired pneumonia; nosocomial pneumonia.

Launch Date

7.5116157E11
Curative
ZERBAXA

Approved Use

ZERBAXA (ceftolozane and tazobactam) is a combination product consisting of a cephalosporin-class antibacterial drug and a beta-lactamase inhibitor indicated for the treatment of complicated Intra-abdominal Infections, used in combination with metronidazole and complicated Urinary Tract Infections, including Pyelonephritis.

Launch Date

1.4189472E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.4 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18 μg/mL
500 mg 3 times / day steady-state, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.4 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TAZOBACTAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15 μg/mL
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
24 μg/mL
375 mg 4 times / day multiple, intravenous
dose: 375 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
34 μg/mL
500 mg 4 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
24.4 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
25 μg × h/mL
500 mg 3 times / day steady-state, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
42.4 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TAZOBACTAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16 μg × h/mL
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
25 μg × h/mL
375 mg 4 times / day multiple, intravenous
dose: 375 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
39.8 μg × h/mL
500 mg 4 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.91 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.03 h
500 mg 3 times / day steady-state, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.13 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.94 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TAZOBACTAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.77 h
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.68 h
375 mg 4 times / day multiple, intravenous
dose: 375 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.82 h
500 mg 4 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
70%
500 mg 3 times / day steady-state, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: CEFTOLOZANE
TAZOBACTAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
70%
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
70%
375 mg 4 times / day multiple, intravenous
dose: 375 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
70%
500 mg 4 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: PIPERACILLIN
TAZOBACTAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Co-administed with::
ceftolozane(2 g; 3/day)
Sources:
healthy, 36
n = 8
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 8
Sources:
Disc. AE: Vomiting...
Other AEs: Nausea, Infusion site inflammation...
AEs leading to
discontinuation/dose reduction:
Vomiting (12.5%)
Other AEs:
Nausea (12.5%)
Infusion site inflammation (12.5%)
Infusion site irritation (25%)
Pain in extremity (12.5%)
Flushing (12.5%)
Sources:
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
healthy, 39
n = 4
Health Status: healthy
Age Group: 39
Sex: M
Population Size: 4
Sources:
Other AEs: Infusion site irritation, Sensation of heaviness...
Other AEs:
Infusion site irritation (25%)
Sensation of heaviness (25%)
Sources:
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 1015
Health Status: unhealthy
Condition: Infections
Age Group: adult
Population Size: 1015
Sources:
Disc. AE: Renal impairment...
AEs leading to
discontinuation/dose reduction:
Renal impairment (0.5%)
Sources:
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Other AEs: Nausea, Headache...
Other AEs:
Nausea (7.9%)
Headache (2.5%)
Diarrhea (6.2%)
Pyrexia (5.6%)
Constipation (1.9%)
Insomnia (3.5%)
Vomiting (3.3%)
Hypokalemia (3.3%)
ALT increased (1.5%)
AST increased (1%)
Anemia (1.5%)
Thrombocytosis (1.9%)
Abdominal pain (1.2%)
Anxiety (1.9%)
Dizziness (0.8%)
Hypotension (1.7%)
Atrial fibrillation (1.2%)
Rash (1.7%)
Sources:
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Other AEs: Anxiety, Dizziness...
Other AEs:
Anxiety (0.2%)
Dizziness (1.1%)
Hypotension (0.4%)
Nausea (2.8%)
Headache (5.8%)
Diarrhea (1.9%)
Pyrexia (1.7%)
Constipation (3.9%)
Insomnia (1.3%)
Vomiting (1.1%)
Hypokalemia (0.8%)
ALT increased (1.7%)
AST increased (1.7%)
Anemia (0.4%)
Thrombocytosis (0.4%)
Abdominal pain (0.8%)
Atrial fibrillation (0.2%)
Rash (0.9%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Flushing 12.5%
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Co-administed with::
ceftolozane(2 g; 3/day)
Sources:
healthy, 36
n = 8
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 8
Sources:
Infusion site inflammation 12.5%
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Co-administed with::
ceftolozane(2 g; 3/day)
Sources:
healthy, 36
n = 8
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 8
Sources:
Nausea 12.5%
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Co-administed with::
ceftolozane(2 g; 3/day)
Sources:
healthy, 36
n = 8
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 8
Sources:
Pain in extremity 12.5%
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Co-administed with::
ceftolozane(2 g; 3/day)
Sources:
healthy, 36
n = 8
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 8
Sources:
Vomiting 12.5%
Disc. AE
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Co-administed with::
ceftolozane(2 g; 3/day)
Sources:
healthy, 36
n = 8
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 8
Sources:
Infusion site irritation 25%
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Co-administed with::
ceftolozane(2 g; 3/day)
Sources:
healthy, 36
n = 8
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 8
Sources:
Infusion site irritation 25%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
healthy, 39
n = 4
Health Status: healthy
Age Group: 39
Sex: M
Population Size: 4
Sources:
Sensation of heaviness 25%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
healthy, 39
n = 4
Health Status: healthy
Age Group: 39
Sex: M
Population Size: 4
Sources:
Renal impairment 0.5%
Disc. AE
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 1015
Health Status: unhealthy
Condition: Infections
Age Group: adult
Population Size: 1015
Sources:
Dizziness 0.8%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
AST increased 1%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Abdominal pain 1.2%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Atrial fibrillation 1.2%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
ALT increased 1.5%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Anemia 1.5%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Hypotension 1.7%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Rash 1.7%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Anxiety 1.9%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Constipation 1.9%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Thrombocytosis 1.9%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Headache 2.5%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Hypokalemia 3.3%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Vomiting 3.3%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Insomnia 3.5%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Pyrexia 5.6%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Diarrhea 6.2%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Nausea 7.9%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 482
Health Status: unhealthy
Condition: Complicated Intra-abdominal Infections
Age Group: adult
Population Size: 482
Sources:
Anxiety 0.2%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Atrial fibrillation 0.2%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Anemia 0.4%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Hypotension 0.4%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Thrombocytosis 0.4%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Abdominal pain 0.8%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Hypokalemia 0.8%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Rash 0.9%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Dizziness 1.1%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Vomiting 1.1%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Insomnia 1.3%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
ALT increased 1.7%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
AST increased 1.7%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Pyrexia 1.7%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Diarrhea 1.9%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Nausea 2.8%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Constipation 3.9%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Headache 5.8%
0.5 g 3 times / day multiple, intravenous
Recommended
Dose: 0.5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 0.5 g, 3 times / day
Co-administed with::
ceftolozane(1 g; 3/day)
Sources:
unhealthy, adult
n = 533
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections, Including Pyelonephritis
Age Group: adult
Population Size: 533
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
unlikely (co-administration study)
Comment: In general, the results of these in vitro trials did not suggest a potential for drug interactions
weak
weak
weak
yes (co-administration study)
Comment: Tazobactam showed some inhibition of CYP3A4 at concentrations well above the expected clinical concentration of 22 µg/mL
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
yes
yes (co-administration study)
Drug as victim
PubMed

PubMed

TitleDatePubMed
[Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].
2001 Jan 10
Faecal concentrations of piperacillin and tazobactam in elderly patients.
2001 Jul
Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization.
2001 Jun 11
Penicillins and beta-lactamase inhibitor combinations.
2001 Jun 15
De-escalation antimicrobial chemotherapy in critically III patients: pros and cons.
2001 Nov
CAPD-associated peritonitis caused by Alcaligenes xylosoxidans sp. xylosoxidans.
2001 Nov-Dec
Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.
2001 Sep
[Identification and susceptibility to antimicrobial agents of strictly anaerobic bacteria isolated from hospitalized patients].
2002
Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis.
2002
[Candida parapsilosis endocarditis after prolonged antibiotic therapy].
2002 Apr
[A multicenter clinical trial of piperacillin/tazobactam in burn infection].
2002 Apr
Gateways to Clinical Trials.
2002 Apr
[Initial empirical antimicrobial therapy with piperacillin/tazobactam in intra-abdominal infections due to perforation of the large intestine and rectum and in postoperative complications after resection of the large intestine and rectum].
2002 Dec
Postoperative infection with group A beta-hemolytic Streptococcus after blepharoplasty.
2002 Dec
Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3.
2002 Dec
Localised necrosis of scrotum (Fournier's gangrene) in a spinal cord injury patient - a case report.
2002 Dec 5
[Study on water of crystallization in tazobactam].
2002 Feb
[In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
2002 Feb
Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue.
2002 Feb
Antibacterial activities of beta-lactamase inhibitors associated with morphological changes of cell wall in Helicobacter pylori.
2002 Feb
[Susceptibility of Pseudomonas aeruginosa to antibiotics isolated from patients of intensive care units in France in 1998. Resistant phenotypes to beta-lactams].
2002 Feb
Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
2002 Feb
Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
2002 Jan
[Piperacillin-tazobactam in the treatment of severe nosocomial infections].
2002 Mar
Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
2002 May 21
Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors.
2002 Nov
Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam.
2002 Nov
Piperacillin/Tazobactam inducing seizures in a hemodialysed patient.
2002 Oct
Susceptibility patterns of Escherichia coli: prevalence of multidrug-resistant isolates and extended spectrum beta-lactamase phenotype.
2002 Sep
Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation.
2002 Sep
Morganella morganii causing solitary liver abscess complicated by pyopericardium and left pleural effusion in a nondiabetic patient.
2002 Sep
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
2002 Sep
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
2002 Sep
[Pharmacokinetics of antibiotics in inflamed and healthy lung tissue].
2003
Bacteraemia and sinusitis due to Flavimonas oryzihabitans infection.
2003
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
2003
[Carbapenem antibiotic ertapenem in the treatment of extrahospital intraabdominal infections].
2003
Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.
2003 Aug
Sciatic nerve palsy as presenting sign of a perianal abscess.
2003 Feb
Current status of drug resistance among gram-negative bacilli isolated from admitted cases in a tertiary care centre.
2003 Jan
Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells.
2003 Jul
Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis.
2003 Jun
Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
2003 Jun
Piperacillin induced bone marrow suppression: a case report.
2003 Jun 5
[beta-Lactamase-inhibitor combinations].
2003 Mar
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
2003 May
[Assay of Acinetobacter SPP drug-resistance by Kirby-Bauer and Etest method].
2003 May
Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
2003 Oct
Intracameral antibiotic agents for endophthalmitis prophylaxis: a pharmacokinetic model.
2003 Sep
Severe acute respiratory syndrome: clinical outcome and prognostic correlates.
2003 Sep
Patents

Patents

Sample Use Guides

The usual daily dose of Zosyn for adults is 3.375 g every 6 h totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). Initial treatment of nosocomial pneumonia should start with Zosyn at a dosage of 4.5 g every 6 h plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). For children with appendicitis and/or peritonitis the recommended Zosyn dosage is 100 mg piperacillin/12.5 mg tazobactam/kg every 8 h in pediatric patients 9 months of age and older. For pediatric patients 2 to 9 months of age, the recommended dosage is 80 mg piperacillin/10 mg tazobactam/kg, every 8 h. The recommended dosage regimen of Zerbaxa is 1.5 g (ceftolozane 1 g and tazobactam 0.5 g) administered every 8 h by intravenous infusion over 1 h in patients 18 years or older and with normal renal function or mild renal impairment.
Route of Administration: Intravenous
In a susceptibility test the minimal inhibitory concentration of 4 ug/ml tazobactam in combination with serial dilutions of piperacillin were <16 mcg/ml for susceptible strains of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii, <1 mcg/ml for susceptible strains of Haemophilus influenzae, <32 mcg/ml for susceptible strains of Bacteroides fragilis group.
Name Type Language
TAZOBACTAM
INN   JAN   MI   USAN   USP   USP-RS   WHO-DD  
USAN   INN  
Official Name English
NSC-759887
Code English
TAZOBACTAM [WHO-DD]
Common Name English
TAZOBACTAM [MI]
Common Name English
TAZOBACTAM [INN]
Common Name English
CL 298,741
Code English
TAZOBACTAM [JAN]
Common Name English
YTR-830H
Code English
TAZOBACTAM [USP]
Common Name English
TAZOBACTAM [USP MONOGRAPH]
Common Name English
TAZOBACTAM [USAN]
Common Name English
TAZOBACTAM [USP-RS]
Common Name English
Classification Tree Code System Code
LIVERTOX 924
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
NDF-RT N0000175930
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
NDF-RT N0000000202
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
NCI_THESAURUS C1500
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
WHO-ATC J01CG02
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
WHO-ATC J01DH51
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
WHO-VATC QJ01CG02
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
Code System Code Type Description
RXCUI
37617
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY RxNorm
FDA UNII
SE10G96M8W
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
NCI_THESAURUS
C62079
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
USP_CATALOG
1643383
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY USP-RS
CAS
89786-04-9
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
WIKIPEDIA
TAZOBACTAM
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
DRUG BANK
DB01606
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
LACTMED
Ceftolozane and Tazobactam
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
INN
6340
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
MERCK INDEX
M10490
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY Merck Index
MESH
C043265
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
LACTMED
Piperacillin and Tazobactam
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
PUBCHEM
123630
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
EVMPD
SUB10849MIG
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
EPA CompTox
89786-04-9
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
ChEMBL
CHEMBL404
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY
DRUG CENTRAL
2572
Created by admin on Fri Jun 25 21:04:50 UTC 2021 , Edited by admin on Fri Jun 25 21:04:50 UTC 2021
PRIMARY